Table 1.
Demographic and clinical characteristics
| N=116 | |
|---|---|
| Sex | |
| Male | 67 (58%) |
| Female | 49 (42%) |
| Age | |
| Median (IQR) | 63 (57, 70) |
| Primary | |
| Lung adeno | 77 (66%) |
| Lung squam | 33 (28%) |
| Lung poorly diff | 6 (5%) |
| Mets category | |
| M0 | 1 (1%) |
| M1a | 44 (38%) |
| M1b | 12 (10%) |
| M1c | 59 (51%) |
| Number of lines of previous tx | |
| 0 | 24 (21%) |
| 1 | 64 (55%) |
| 2 | 23 (20%) |
| 3 | 2 (2%) |
| 4 | 2 (2%) |
| 5 | 1 (1%) |
| Agent | |
| Pembro | 21 (18%) |
| Pembro plus chemo | 15 (13%) |
| Pembro plus investigational | 7 (6%) |
| Pembro plus ipi | 8 (7%) |
| Nivo | 65 (56%) |
| Protocol | |
| No | 71 (61%) |
| Yes | 45 (39%) |
| Best responsea | |
| PR | 26 (26%) |
| SD | 39 (39%) |
| PD | 34 (34%) |
| Not recorded | 4 (4%) |
| Reason for discontinuation | |
| Progression | 37 (32%) |
| PD-1 Adverse events | 16 (14%) |
| PS Decline, hospital admit, hospice | 43 (37%) |
| Completed therapy | 11 (10%) |
| Unknown, lost | 6 (5%) |
| Long vacation | 1 (1%) |
| No response | 2 (2%) |
| Hospitalization within 6 weeks of first dosea | |
| No | 78 (76%) |
| Yes | 25 (24%) |
| Total volume, median (IQR) | |
| Median (IQR) | 53.7 (13.3, 107.9) |
| Lung volume | |
| Median (IQR) | 15.1 (0.0, 65.4) |
| Unmeasurable lung | |
| No | 27 (23.3%) |
| Yes | 89 (76.7%) |
| LN volume | |
| Median (IQR) | 5.1 (0.0, 18.1) |
| Unmeasurable LN | |
| No | 43 (37.1%) |
| Yes | 73 (62.9%) |
| Liver volume | |
| Median (IQR) | 0.0 (0.0, 0.0) |
| Unmeasurable liver | |
| No | 93 (80%) |
| Yes | 23 (20%) |
| Soft tissue volume | |
| Median (IQR) | 0.0 (0.0, 0.0) |
| Unmeasurable soft tissue | |
| No | 85 (73%) |
| Yes | 31 (27%) |
Notes: aFor those followed for at least weeks.
Abbreviations: SD, stable disease; PD-1, program death-1; PR, partial response; LN, lymph node; PS, performance status; PD, progression of disease.